MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
Dosing is progressing on schedule in ongoing ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in…
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6…
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated…
ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs…
Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platformThe collaboration will access mRNA technology from the…
Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) And Internal Debt Restructuring First regulatory agency…
H3N2 HAI Response Vaccination with PDS0202 Provides broadly effective HAI antibody responses (minimum 1:40 ratio) across multiple strains of the…
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV…
POLITICS: Medical Marijuana Company Slams DEA In Lawsuit Alleging Extreme Delays To Cannabis Research LicensingWASHINGTON, D.C. / ACCESSWIRE / September…